Pediatric Cancer Clinical Trial Finder
We believe that patients and families should have tools available to help make the search for treatments easier. For that reason, we’ve developed a Pediatric Cancer Clinical Trial Navigator for CAR T-cell therapy and other immunotherapy treatments. Use the filters to display relevant trials. Clicking on a card will allow you to access more detailed information, including contact information, for each clinical trial.
Genetic
Biological
Drug
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
U.S.
TX
Recruiting
Learn More
Genetic
Biological
Drug
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)
U.S.
TX
Recruiting
Learn More
Genetic
Biological
Drug
Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
U.S.
PA
Recruiting
Learn More
Genetic
Biological
Drug
CTL019 Out of Specification MAP for ALL or DLBCL Patients
U.S.
AL,
AR,
CA,
CO,
FL,
GA,
IL,
IN,
IA,
MA,
MD,
MI,
MN,
NE,
NJ,
NY,
OH,
OR,
PA,
SC,
TN,
TX,
UT,
VA,
WI,
WV
Other
Learn More
Genetic
Biological
Drug
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
U.S.
WA
Recruiting
Learn More
Genetic
Biological
Drug
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
U.S.
MD
Recruiting
Learn More
Genetic
Biological
Drug
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
U.S.
MD
Recruiting
Learn More
Genetic
Biological
Drug
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)
U.S.
TX
Recruiting
Learn More
Genetic
Biological
Drug
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
U.S.
WA
Recruiting
Learn More
Genetic
Biological
Drug
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia (PLAT-01)
U.S.
WA
Active, not recruiting
Learn More
Recruiting
Learn More